Citigroup Inc. Buys 14,512 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Citigroup Inc. raised its position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 100.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,965 shares of the medical instruments supplier's stock after purchasing an additional 14,512 shares during the period. Citigroup Inc. owned approximately 0.12% of ICU Medical worth $5,278,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ICUI. Innealta Capital LLC bought a new stake in shares of ICU Medical in the second quarter worth $32,000. Hexagon Capital Partners LLC boosted its position in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 122 shares during the last quarter. Allworth Financial LP boosted its position in ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 100 shares during the last quarter. Venturi Wealth Management LLC boosted its position in ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier's stock valued at $59,000 after acquiring an additional 302 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in ICU Medical during the second quarter valued at $70,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ICUI has been the topic of a number of research analyst reports. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a "hold" rating and a $183.00 price target on the stock. KeyCorp increased their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 13th. Raymond James increased their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a research report on Thursday, September 12th. StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, ICU Medical has an average rating of "Moderate Buy" and an average target price of $173.00.

Insider Buying and Selling at ICU Medical

In other news, COO Christian B. Voigtlander sold 1,430 shares of the firm's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $158.00, for a total transaction of $225,940.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the firm's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $18,665,666.78. This trade represents a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,364 shares of company stock valued at $6,869,878 in the last three months. Company insiders own 6.70% of the company's stock.

ICU Medical Trading Down 2.7 %

Shares of ICU Medical stock traded down $4.32 on Tuesday, reaching $156.64. 240,364 shares of the company traded hands, compared to its average volume of 273,838. The company has a 50 day moving average of $174.32 and a 200 day moving average of $148.06. ICU Medical, Inc. has a 52 week low of $83.26 and a 52 week high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.